A Tissue Plasminogen Activator (tPA) or clot-busting drug was the only effective and proven therapy for ischemic strokes. Mechanical thrombectomy is the novel treatment option for patients suffering from ischemic stroke. Mechanical thrombectomy is an advanced treatment for stroke that eradicates blood clots from the brain’s large blood vessels. A significant percentage of the acute stroke patient populace is entitled to treatment with thrombolysis. In 2018, according to the NHS England commissionary policy, approximately 12% of all individuals with stroke were qualified for mechanical thrombectomy treatment. The rising prevalence of stroke and growing demand for effective treatment are expected to propel the growth of these devices over the forecast period.
The Mechanical Thrombectomy Devices Market is a segment based on product type, application, end-user, and geography. Based on product type, the global mechanical thrombectomy devices market is segmented into stent retriever devices, coil retriever devices, aspiration devices, and others (ultrasound-based devices). Stryker’s Merci Retriever system and Penumbra’s Penumbra Aspiration device are the first generations mechanical thrombectomy devices. Moreover, the growing FDA approvals and ongoing research activities are expected to propel the growth of the market in the coming years. Stent retriever devices are estimated to account for the significant share in the global mechanical thrombectomy devices market in 2019, owing to the growing use of these devices in past years. Moreover, growing strategic activities among the key players operating in the market are projected to propel the growth of the market significantly during the estimated timeframe.
Based on application, the market is segmented into the stroke, deep vein thrombosis (DVT), pulmonary embolism (PE), arteriovenous fistula (AVF), peripheral arterial disease (PAD), hemodialysis treatments, and others. By end-user, the global mechanical thrombectomy devices market is segmented into hospitals, ambulatory surgical centers, specialty clinics, and academic & research institutes. In 2019, the hospitals accounted for a significant share in the global mechanical thrombectomy devices market. The presence of a vast number of multispecialty hospitals enhanced reimbursement policies for neurovascular and cardiovascular disorders, and availability of well-trained health care specialists are contributing towards the high share of hospitals in the global market. The ambulatory surgical centers are expected to register high CAGR during the forecast period. The growing demand for invasive surgical procedures and the rising number of ambulatory surgical centers are propelling the growth of the segment in the global market.
Based on geography, the Global Mechanical Thrombectomy Devices Market has been segmented into North America, Asia Pacific, Latin America, Europe, and Middle East & Africa. In 2019, North America is accounted for a significant share in the global mechanical thrombectomy devices market. The presence of large numbers of companies operating in the market, high adoption of technically advanced products, well-established healthcare infrastructure and are some of the significant factors contributing to the high share of the market in the region. Additionally, growing demand for minimally invasive surgeries in the area is expected to propel the growth of the North America mechanical thrombectomy devices market over the estimated timeframe.
Some of the market players leading the Global Mechanical Thrombectomy Devices Market include Boston Scientific Corporation, Straub Medical AG, AngioDynamics, Acandis GmbH, NIPRO, Medtronic, MicroVention, Inc., Stryker Corporation, Phenox GmbH, Penumbra, Inc., Balt Extrusion, Medrad Inc. (Bayer HealthCare LLC), Johnson & Johnson, Rapid Medical Inc., and Anaconda Biomed SL among others.